Biocartis Group NV Overview
| Field | Biocartis Group NV (listed entity, in liquidation) | Continuing operating business |
|---|---|---|
| Legal name | Biocartis Group NV (in vereffening / in liquidation) | Biocartis NV (Belgium); Biocartis US Inc. (USA); parent Biocartis Holdings Inc. |
| Former names / predecessors | Biocartis SA (Lausanne, Switzerland) was the original group vehicle; the group later redomiciled to Mechelen, Belgium (date not re-verified) | Same Idylla business; "New Biocartis" in 2023 restructuring documents |
| Founding year | 2007 (company and aggregator profiles) | 2007 (business origin) |
| Incorporation jurisdiction | Belgium (NV under the Belgian Code of Companies and Associations) | Biocartis NV: Belgium; Biocartis US Inc.: USA; Biocartis Holdings Inc.: not publicly disclosed (US corporation per name; state not disclosed) |
| Headquarters | Generaal de Wittelaan 11B, 2800 Mechelen, Belgium | Mechelen, Belgium (manufacturing and R&D); US operations (location not publicly disclosed in sources reviewed) |
| Exchange / ticker | Euronext Brussels: BCART (trading suspended by FSMA in September 2023; some data vendors classify it as delisted since September 2023); US OTC quote BIOGF (inactive) | Not listed |
| ISIN | BE0974281132 | — |
| LEI | 549300J4HOJL5KG8HY54 (financialfilings.com) | — |
| CUSIP | Not applicable / not publicly disclosed | — |
| Fiscal year end | 31 December | 31 December (assumed; not publicly disclosed) |
| Employees | 526 full-time (Yahoo Finance profile, latest reported group figure, likely FY2022). After the 2023 transfer the listed entity has effectively no operating staff. | About 200 employees in Mechelen (Made in / KBC Securities commentary, August 2025) |
| Auditor | not re-verified) | — |
| Market capitalisation | Effectively nil economic value. Last trade about EUR 0.29/share in September 2023; about EUR 27.2M on about 93.9M shares (Parqet/Craft aggregator data) | Private; valuation not publicly disclosed |
| Website | biocartisgroupnv.be (investor/liquidation notices); historical biocartis.com | biocartis.com |
| Liquidator | Mr. Kristiaan Caluwaerts (appointed 15 December 2025) | — |
| Controlling owners | Shareholders of the shell have no residual claim on the operating business | Former secured bondholders and first-lien lenders. KBC Securities identifies US hedge funds Whitebox and Highbridge as the key holders (Made in, 28 August 2025) |
| Metric | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Group FTE headcount (number) | — | — | 526 |
The 526 figure comes from the Yahoo Finance profile and its reference year is not stated. A cost-reduction and operational reorganisation programme announced on 15 June 2023 cut functions during 2023 (H1 2023 results release, 26 September 2023). Around 200 Mechelen jobs were reported as maintained under the new owners in August 2025.
Biocartis built Idylla, a fully automated, cartridge-based real-time PCR system that runs "sample-to-result" molecular tests directly from routine clinical samples, notably formalin-fixed paraffin-embedded (FFPE) tumour tissue, in about three hours with minimal hands-on time. Its strategic niche was decentralised oncology biomarker testing (BRAF, KRAS, NRAS, EGFR, MSI, gene fusions) for hospital pathology labs that lack next-generation sequencing (NGS) capacity or need faster turnaround than send-out sequencing. Commercial traction was real: about 2,200 instruments installed and more than 330,000 cartridges a year by 2022–2023. Losses were structural, however: cumulative losses approached EUR 0.5 billion, and a EUR 150M convertible bond overhang proved unserviceable. The listed holding company was hollowed out by creditor enforcement in October 2023 and is now in judicial liquidation. The operating franchise survives privately and has since won its first FDA premarket approval for a companion diagnostic (Idylla CDx MSI, September 2025).
What the company does
Biocartis develops, manufactures and sells the Idylla molecular diagnostics platform. The system has three parts:
-
the Idylla Instrument, a cartridge-processing module, with several modules connectable to one console;
-
the Idylla Console, the user interface and data management unit;
-
single-use Idylla cartridges, each a self-contained assay with all reagents pre-loaded.
The user places a sample, such as an FFPE tissue slice, plasma or a swab, into the cartridge. The cartridge performs liquefaction and nucleic-acid extraction, amplification and real-time PCR detection with no further intervention. The company describes Idylla's proprietary liquefaction sample preparation as the reason it can handle difficult samples such as small tissue biopsies and FFPE material (CEO Roger Moody, 360Dx interview, September 2025).
The menu historically covered two areas:
Oncology: (core): mutation tests for colorectal cancer, lung cancer and melanoma; MSI status; a lung gene-fusion panel; plus research-use assays and partner-developed tests such as Merlin (SkylineDx, melanoma), Hepatopredict (Ophiomics, liver cancer) and ColonoDETECT.
Infectious disease: Idylla SARS-CoV-2 and SARS-CoV-2/Flu/RSV panels, and the SeptiCyte RAPID host-response sepsis test (licensed from Immunexpress).
Business model and revenue model
| Revenue stream | Description | FY2022 figure (EUR Mn) | Share of FY2022 revenue |
|---|---|---|---|
| Cartridge sales (product) | Consumable assays: oncology plus infectious disease | 35.9 | about 62% |
| Instrument sales and rentals (product) | Idylla systems sold to end users and content partners, plus rental income | 9.2 | about 16% |
| Collaboration revenue | R&D services and milestones from pharma CDx partners and content partners | about 12 (derived) | about 21% |
| Service revenue | Instrument servicing | included above (service revenue was EUR 1.7M in FY2021) | about 2–3% |
| Total revenue | — | 57.5 | 100% |
Biocartis ran a classic razor/razor-blade installed-base model. Instruments were sold, rented or placed free under evaluation programmes, and recurring revenue came from cartridge consumption. Revenue had four lines:
Source: Biocartis FY2022 results press release, 23 February 2023. Collaboration plus service is derived as total revenue (57.5) minus product revenue (45.0). There was no subscription model. Licensing appeared mainly in-bound, with partner content (Immunexpress, SkylineDx, Ophiomics, GeneproDx) commercialised on Idylla, sometimes under revenue-share arrangements.
Pricing signals disclosed:
-
Average selling price (ASP) per commercial cartridge: EUR 106 in FY2022 versus EUR 96 in FY2021; oncology ASP EUR 116 (+11%) (FY2022 results).
-
Oncology ASP in Q1 2022: EUR 114; all products: EUR 101 (GenomeWeb, Q1 2022).
-
Free evaluation programme: a customer could temporarily use an instrument while paying only for cartridges consumed (FY2022 results).
Value-chain position
Biocartis was vertically integrated from assay design to manufacturing. Cartridges were produced in Mechelen, including a high-throughput, fully automated manufacturing line that was ramping in 2022, and the company sold through a hybrid of direct sales (Europe, US) and distributors:
-
Nichirei Biosciences in Japan;
-
third-party distributors in rest-of-world markets.
Pharma companies acted both as customers, funding companion diagnostic (CDx) development, and as demand creators, because a CDx label pulls testing into labs.
Customers and end-markets
| Customer type | Role | Evidence |
|---|---|---|
| Hospital pathology and molecular labs | Core users of oncology cartridges | Several new top-10 cancer centres adopted Idylla in 2022 (FY2022 results) |
| Reference and community labs (US) | Growth target of the US go-to-market model from 2019 | New US direct sales strategy, September 2019 |
| Pharmaceutical companies | CDx development partners funding R&D | Amgen (RAS), Bristol Myers Squibb (MSI), AstraZeneca (EGFR/osimertinib CDx) |
| Content partners / diagnostic developers | Port their tests onto Idylla | SkylineDx, Ophiomics, Immunexpress, GeneproDx, Apis Assay Technologies, HiloProbe |
| Clinical trial sponsors | Instruments for trial sites | Clinical-trial-driven instrument purchases deferred into 2023 (Q3 2022 update) |
| Academic medical centres | Research collaborations on new signatures | Mayo Clinic, Medical College of Wisconsin, City of Hope (2026) |
Company self-description versus independent characterisation
Company's own description (paraphrased from "About Biocartis" boilerplate, 2022–2023 releases): Biocartis presents itself as an innovative molecular diagnostics company whose proprietary, fully automated Idylla platform aims to make precision medicine accessible by delivering fast, accurate molecular information from virtually any biological sample, with a continuously expanding oncology menu.
Independent characterisation: Biocartis was a technologically differentiated but sub-scale single-platform MDx vendor. It was caught between two groups:
-
integrated rapid-PCR players with large installed bases and broad infectious-disease menus, notably Cepheid's GeneXpert;
-
an oncology testing paradigm that steadily shifted toward multi-gene NGS panels.
Idylla's sweet spot was single-gene or small-panel testing where speed and tissue economy matter. That segment is real but narrower than the company's early-stage valuation implied. Revenue grew at about 15% CAGR from FY2019 to FY2022, but gross margin on products only reached the mid-30s percent in 2022 and 40% in H1 2023. Operating cash burn stayed far above revenue capacity, which ultimately transferred the equity to creditors.
Strategy
Stated strategy themes (last listed period, 2022–2023)
-
Drive profitable growth: grow product revenue, expand product gross margins through ASP increases and manufacturing automation, and cut operating cash burn (2022 key objectives, 17 January 2023 release).
-
Oncology focus: concentrate on high-value oncology cartridges and de-emphasise infectious disease after COVID-19.
-
Menu expansion via partners: become an open platform for third-party content (SkylineDx, Ophiomics, Apis, HiloProbe, GeneproDx, Immunexpress).
-
Pharma CDx: secure CDx claims (BMS MSI, AstraZeneca EGFR, Amgen RAS) to pull Idylla into standard-of-care testing.
-
US commercial build-out: direct sales model; the CEO appointment in 2023 was explicitly aimed at US commercial success.
Initiatives in the last 24 months (operating business, October 2024 – October 2026)
| Date | Initiative | Type | Strategic intent |
|---|---|---|---|
| Mar 2025 | Multiple USCAP 2025 abstracts on Idylla | Clinical evidence | Build real-world utility data |
| 2 Jun 2025 | IVDR Class C CDx certification, Idylla EGFR Mutation Test | Regulatory | Secure EU market access under IVDR |
| Jun–Aug 2025 | New SVPs in Global Marketing (Svarczkopf) and Global Business Development (Kreitzinger) | Leadership | Commercial and partnering push |
| 15 Sep 2025 | FDA PMA for Idylla CDx MSI Test (with BMS) | Regulatory / CDx | First US CDx; reposition as the "sample-to-result CDx" platform |
| Nov 2025 | AMP 2025 showcase | Marketing | US lab adoption |
| 12 Jan 2026 | Mayo Clinic collaboration (breast cancer gene signatures) | R&D partnership | Move up the value chain into multigene signatures |
| 10 Mar 2026 | IVDR CDx certification for Idylla CDx MSI | Regulatory | EU CDx parity |
| 24 Mar 2026 | Medical College of Wisconsin collaboration (breast signatures) | R&D partnership | Same |
| 9 Jun 2026 | City of Hope agreement (pancreatic cancer early-detection signature) | R&D partnership | Entry into early detection |
| 7 Jul 2026 | Discovery Life Sciences strategic collaboration | Commercial / biopharma services | Access biopharma trial and biospecimen ecosystem |
Cost programmes and targets
2022: target to cut operating cash burn by EUR 9.5M–13.5M; actual reduction was EUR 18.1M.
2023: EBITDA guidance of EUR -25M to -28M. A reorganisation and cost-reduction programme announced 15 June 2023 had targets that were not fully disclosed in the sources reviewed.
Post-restructuring plan: the EUR 40M new equity was meant to fund the business to EBITDA break-even by end-2024 (recapitalisation release, 26 September 2023). By September 2025 the CEO said the company was on a pathway to profitability "within the next year", which implies break-even slipped by at least a year.
ESG commitments
No quantified ESG targets were disclosed. Sustainability reports were published from 2015 to 2022 (sustainabilityreports.com index lists nine reports).
Medium-term targets
No current financial guidance exists for the listed entity, which is in liquidation. The operating business has disclosed no quantified medium-term targets beyond the profitability ambition above.
Products & Services
All products sit within the single Idylla segment.
Platform hardware
| Product | Description and capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Idylla Instrument | Cartridge-processing module running automated sample prep, PCR and detection; modules stackable on one console | Pathology and molecular labs | c. 2014 launch (not re-verified); China approval 2022 | Installed base 2,218 at end of H1 2023 |
| Idylla Console | Touch-screen control and data unit linking multiple instruments | Same | c. 2014 | Part of the system |
| Idylla FLEX | Platform enhancement announced February 2023 to increase flexibility (detailed specifications not publicly disclosed in sources reviewed) | Labs, content partners | 2,023 | Q1 2023 release links |
Oncology tests: IVD / CDx
| Test | Clinical use | Key features | Regulatory status (latest known) |
|---|---|---|---|
| Idylla BRAF Mutation Test | Melanoma / colorectal BRAF V600 status | FFPE-to-result, about 90 minutes to 3 hours | CE-IVD (Europe) |
| Idylla KRAS Mutation Test | Colorectal cancer therapy selection | FFPE | CE-IVD; Amgen RAS collaboration |
| Idylla NRAS-BRAF Mutation Test | Colorectal cancer / melanoma | FFPE | CE-IVD |
| Idylla EGFR Mutation Test | NSCLC EGFR status | FFPE | IVDR Class C CDx certification (2 June 2025); AstraZeneca CDx collaboration for osimertinib |
| Idylla MSI Test | Microsatellite instability in colorectal cancer (Lynch screening / immunotherapy selection) | Seven novel MSI biomarkers; no matched normal tissue required (not re-verified) | CE-IVD 2019; Japan approval via Nichirei 2022 |
| Idylla CDx MSI Test | Companion diagnostic for colorectal cancer, developed with Bristol Myers Squibb | First fully automated cartridge-based CDx approved in the US for CRC | FDA PMA (15 September 2025); IVDR Class C CDx (10 March 2026) |
| Idylla GeneFusion Panel | NSCLC fusion screening (ALK, ROS1, RET, NTRK, MET exon 14; not re-verified) | Lower tissue requirement, faster turnaround than standard methods | CE-IVD, launched 20 June 2022 |
| Idylla ctEGFR Mutation Assay | EGFR from plasma (liquid biopsy) | Research use | Launched 2019 |
Oncology: partner-content and research assays
| Assay | Partner | Use | Status |
|---|---|---|---|
| Merlin Assay (CP-GEP) | SkylineDx | Melanoma: identifies patients who may safely forgo sentinel lymph node biopsy | European commercialisation started September 2022 |
| Idylla Hepatopredict | Ophiomics | Liver cancer: transplant/resection eligibility prognostic | Partnership February 2022 |
| ColonoDETECT | — | Colorectal | Listed in portfolio (roic.ai) |
| ThyroidPrint | GeneproDx | Thyroid nodule genomic classifier | License, development and commercialisation agreement |
| Breast cancer subtyping assay | Apis Assay Technologies | Breast cancer molecular subtyping | Agreement April 2023 |
| Colorectal cancer test | HiloProbe | CRC | Collaboration 2023 |
| Oncology research assays (RUO) | In-house | Biomarker research | Ongoing |
Infectious disease
| Test | Use | Status |
|---|---|---|
| Idylla SARS-CoV-2 Test | COVID-19 PCR | Launched 2020; revenue fell from EUR 6.8M (FY2021, derived) to EUR 3.5M (FY2022) and EUR 0.7M (H1 2023) |
| Idylla SARS-CoV-2/Flu/RSV Panel | Respiratory multiplex | Launched (year not re-verified) |
| SeptiCyte RAPID on Idylla | Host-response test to distinguish sepsis from non-infectious systemic inflammation (Immunexpress) | Market release announced (year not re-verified) |
Pipeline (operating business, 2025–2026)
| Programme | Description | Source |
|---|---|---|
| ESR1 test | Supported by preliminary SERENA-6 trial data (breast cancer, ESR1 mutations) | CEO Moody, 360Dx, September 2025 |
| Breast cancer gene signatures | Collaborations with Mayo Clinic (January 2026) and Medical College of Wisconsin (March 2026) | Biocartis newsroom |
| Pancreatic cancer early-detection signature | Rapid gene-signature test with City of Hope | Biocartis newsroom, 9 June 2026 |
| PCR-based cancer panel reimbursement advocacy | US policy agenda | 360Dx, September 2025 |
Services
Instrument servicing and maintenance, a free evaluation and placement programme, and R&D services to pharma and content partners (collaboration revenue).
Financial Narrative
Basis: IFRS as adopted by the EU, EUR millions unless stated. The five fiscal years are FY2019–FY2023, the last five years of the listed group's reporting. FY2024 and FY2025 are not applicable: after 31 October 2023 the listed group had no operating business, and the private operating group does not publish accounts.
Primary limitation: FY2023 full-year audited figures were delayed (the annual report was postponed in May 2024). FY2023 columns are therefore mostly blank, and the H1 2023 data is the most reliable late-period information.
Income statement
Sources and notes:
-
FY2019–FY2021 revenue, net loss, EPS, R&D and SG&A: GenomeWeb/360Dx summaries of results releases. Total operating income FY2020–FY2022: Biocartis results releases.
-
FY2022: Biocartis FY2022 results (23 February 2023) and GenomeWeb.
-
FY2022 gross profit (27.7) and the alternative net loss (-65.4) and EBITDA (-44.3) come from Parqet aggregator data. Discrepancy: GenomeWeb reports an FY2022 net loss of EUR 47.7M (EPS -0.79), while Parqet shows -65.4M. The gap may reflect gains on convertible bond repurchases or different line definitions. The primary-source-adjacent GenomeWeb figure is used in the table.
EBITDA derivation: FY2023 guidance was EBITDA of EUR -25M to -28M, an improvement of EUR 8.5M–11.5M, which implies FY2022 EBITDA of about EUR -36.5M. That conflicts with Parqet's -44.3M. FY2021 EBITDA is not directly disclosed; -46.0 is an estimate from FY2021 operating cash burn of EUR 56.6M less assumed capex of about EUR 10M and should be treated as indicative only.
-
Diluted EPS equals basic EPS in all years given losses (anti-dilutive instruments).
-
FY2018 reference: revenue EUR 27.8M; net loss EUR 48.2M; EPS -0.94.
Margins and growth
Product gross margin is gross profit on product sales divided by product revenue. Management reported a 34% year-end 2022 gross margin, 35% in Q1 2023 and 40% in H1 2023. Net margin uses GenomeWeb net loss figures.
Revenue CAGR FY2019–FY2022: about 15.4% total revenue and about 23.2% product revenue (derived).
Balance sheet
Sources: annual results summaries; the FY2021 cash figure includes EUR 6.0M drawn on short-term facilities; the 2023 restructuring figure is from the recapitalisation release of 26 September 2023.
The following balance-sheet items were not publicly disclosed in the sources retrieved: total assets, equity, goodwill and intangibles, working capital, and the short/long-term split of total debt for FY2019–FY2022. The qualitative capital structure is set out below.
Capital structure evolution:
Shares outstanding: about 93.92M (Parqet).
Cash flow
Sources and notes:
-
Operating cash burn: Biocartis results releases (FY2022: "a reduction of more than a third").
-
Net change in cash is derived from year-end cash balances and includes financing flows.
-
Operating cash flow, capex and free cash flow as separate lines are not publicly disclosed in the sources retrieved. The operating cash burn measure (EBITDA plus capex) is the company's own free-cash-flow proxy.
Ratios
ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful or not publicly disclosed. EBITDA and net income were negative throughout, and Parqet reports a negative price-to-book of -0.58, indicating negative book equity by 2023. The December 2025 court judgment confirmed negative net equity as the legal ground for dissolution.
Commentary: trends, inflections and drivers
FY2019–FY2020: growth phase financed by IPO and convertible cash.
-
Revenue rose from EUR 27.8M (FY2018) to EUR 43.1M (FY2020).
-
The installed base grew from 1,310 to 1,581 instruments, and cartridge volume from about 175k to about 230k (+31%).
-
Net losses held at about EUR 63–64M a year as R&D climbed to EUR 45.8M, above 100% of revenue.
-
Cash fell from EUR 178.7M to EUR 123.7M.
-
COVID-19 disrupted instrument placements in H1 2020 (101 versus 156 a year earlier) but brought a temporary infectious-disease tailwind via Idylla SARS-CoV-2.
FY2021: the inflection that never paid off.
-
Product revenue grew 27% to EUR 40.5M, but collaboration revenue fell 39% to EUR 6.1M.
-
A manufacturing-line fire interrupted the high-throughput line.
-
The net loss peaked at EUR 71.5M, and cash dropped to EUR 53.5M (including EUR 6M of drawn facilities).
-
The 2022 guidance of EUR 50–55M product revenue proved far too optimistic.
FY2022: margin repair, guidance miss and recapitalisation.
-
Product revenue reached EUR 45.0M, missing the original EUR 50–55M guidance; it was revised down to "at least EUR 45M" in October 2022 because of deferred clinical trials, customer destocking and greater use of free evaluations.
-
Product gross profit more than doubled, from EUR 6.6M to EUR 15.2M, thanks to rising oncology ASPs (EUR 116) and automation scale effects.
-
Operating cash burn fell by EUR 18.1M to EUR 38.5M.
-
Cash nonetheless fell to EUR 26.1M, and the company needed the EUR 66M rescue package, which pushed further debt onto the balance sheet.
FY2023: operational improvement overtaken by the capital structure.
-
H1 2023 revenue grew 12% to EUR 29.5M, gross margin reached 40% and EBITDA improved to EUR -14.5M.
-
Total debt of more than EUR 170M (EUR 132M of bonds plus secured loans) against a market cap below EUR 30M meant equity holders were out of the money.
-
Creditors chose enforcement over another dilutive refinancing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue stream (EUR Mn)
| Revenue stream (EUR Mn) | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Product revenue (cartridges plus instruments) | 24.1 | 31.9 | 40.5 | 45.0 | — |
Collaboration revenue | 12.5 | 10.0 | 6.1 | — | — |
Service revenue | 0.8 | 1.2 | 1.7 | — | — |
Total revenue | 37.4 | 43.1 | 48.3 | 57.5 | 47.4 |
Product Lines
| Product line (EUR Mn) | FY2021 | FY2022 |
|---|---|---|
Cartridge revenue, total | — | 35.9 |
Oncology cartridge revenue | 24.1 | 31.3 |
SARS-CoV-2 product revenue | 6.8 | 3.5 |
Instrument revenue (sales and rentals) | 8.9 | 9.2 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
Total revenue growth YoY | 15.2 | 12.1 | 19.0 |
Product revenue growth YoY | 32.4 | 27.0 | 11.1 |
Collaboration revenue growth YoY | -20.0 | -39.0 | — |
Product share of total revenue | 74.0 | 83.9 | 78.3 |
Revenue by Segment
| Metric (EUR Mn) | H1 2022 | H1 2023 |
|---|---|---|
Total revenue | 26.4 | 29.5 |
Product-related revenue | 21.3 | 23.5 |
Collaboration revenue | 5.1 | 6.0 |
SARS-CoV-2 revenue | 1.7 | 0.7 |
EBITDA | -18.2 | -14.5 |
Net loss | -28.8 | -31.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric (EUR Mn) | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Total revenue | 37.4 | 43.1 | 48.3 | 57.5 | 47.4 |
Total operating income (incl. grants and other) | — | 55.6 | 54.9 | 58.0 | — |
Gross profit on product sales | — | — | 6.6 | 15.2 | — |
Gross profit (total, aggregator) | — | — | — | 27.7 | — |
R&D expenses | 39.8 | 45.8 | 48.0 | — | — |
SG&A expenses | — | 30.3 | 32.4 | — | — |
EBITDA (company-implied) | — | — | -46.0 | -36.5 | — |
Net loss | -64.1 | -62.9 | -71.5 | -47.7 | — |
EPS basic (EUR) | -1.14 | -1.11 | -1.26 | -0.79 | — |
Dividends per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Revenue growth YoY | 34.5 | 15.2 | 12.1 | 19.0 |
Product gross margin | — | — | 16.3 | 33.8 |
EBITDA margin (implied) | — | — | -95.2 | -63.5 |
Net margin | -171.4 | -145.9 | -148.0 | -83.0 |
R&D as % of revenue | 106.4 | 106.3 | 99.4 | — |
Key Financials
| Metric (EUR Mn) | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Cash and cash equivalents | 178.7 | 123.7 | 53.5 | 26.1 | — |
Short-term credit facilities drawn | — | — | 6.0 | — | — |
Bonds equitised in 2023 restructuring | — | — | — | — | 132.0 |
Capital Instruments
| Instrument | Key terms | Status | Source |
|---|---|---|---|
Convertible bonds due 2024 | EUR 150M, 4% coupon, issued 2019 | Partially repurchased and exchanged in 2022 (about EUR 14M used to repurchase more than EUR 16M principal in October 2022) | — |
New convertible notes (2022) | EUR 41M new money within the EUR 66M recapitalisation; maturity extended (stated as pushing out convertible maturity) | Equitised or enforced in 2023 | H1 2022 / FY2022 results |
Senior secured term loan | EUR 30M total; about EUR 18M drawn 19 October 2022 | Lenders became owners via enforcement | Q3 2022 update |
Equity raise (2022–2023) | EUR 25M | Completed January 2023 | FY2022 results |
Post-restructuring "New Biocartis" | EUR 132M bonds equitised plus EUR 40M new equity; about EUR 44.5M gross debt, about zero net debt | Executed October 2023 | 360Dx, 26 September 2023 |
2024 convertible bonds | Remaining principal after 2022 exchange and repurchase not publicly disclosed | 2,024 | Equitised or enforced 2023 |
2022 new convertible notes | About EUR 41M new money plus exchanged amounts | — | Equitised or enforced 2023 |
Senior secured term loan | EUR 30M facility (about EUR 18M drawn October 2022) | — | Rolled into the New Biocartis structure |
New Biocartis gross debt (post-October 2023) | About EUR 44.5M | — | Private |
“—” = not publicly disclosed.
Cash Flow
| Metric (EUR Mn) | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Operating cash burn (EBITDA plus capex) | — | — | -56.6 | -38.5 | — |
Net change in cash | — | -55.0 | -70.2 | -27.4 | — |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Financial Analysis
| Ratio | FY2021 | FY2022 |
|---|---|---|
Cash burn as % of revenue | 117.2 | 67.0 |
Region Overview
| Region | Model | Disclosed growth signals | Assessment |
|---|---|---|---|
Europe | Direct sales in core markets plus distributors | Robust European cartridge growth even during COVID-19 (H1 2020); continued growth in 2022, helped by the GeneFusion Panel | Historic core; largest revenue base; IVDR certification in 2025–2026 strengthens the regulatory moat |
United States | Direct sales from September 2019 | US instrument revenue more than doubled in 2022; oncology cartridge growth "led by the US" (FY2022 results); 2019 problem that US cartridge consumption lagged placements | Fastest-growing region in 2022; strategic priority under US-based CEO Moody; FDA CDx MSI PMA (2025) is the key US catalyst |
Japan | Distributor (Nichirei Biosciences) | Idylla MSI approval in Japan in 2022 | Niche, partner-dependent |
China | Joint venture (2019) | NMPA instrument compliance testing in January 2020; instrument approval in 2022 | Slow; revenue contribution not publicly disclosed |
Russia / other RoW | Distributors | Impact of lost Russian distributor sales after the 2022 invasion described as not material | Minor |
Share Price
| Metric (EUR) | FY2015 | FY2023 |
|---|---|---|
Reference share price | 11.50 | 0.29 |
Return window
| Return window | Value | Note |
|---|---|---|
5-year | about -95% or worse | — |
Since IPO | about -97.5% | EUR 11.50 to EUR 0.29 |
Economic value to shareholders | about -100% | No distribution from enforcement; liquidation with negative equity |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None current. KBC Securities (Tom Simonts) covered the stock historically |
Dividend history and policy | No dividends ever paid |
Buyback authorisations | None executed |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Analyst Conclusions
Guidance
Biocartis Group NV: no guidance. The entity is in judicial liquidation. Its residual assets go to creditors under the liquidator's control, and shareholders are expected to receive nothing.
Operating business: management targets profitability on a roughly 12-month horizon from September 2025. That implies break-even around H2 2026, which has not been publicly confirmed as achieved.
Consensus: none.
Bull case (operating franchise)
-
CDx flywheel: the FDA PMA for Idylla CDx MSI and IVDR CDx certifications for MSI and EGFR give Idylla a regulated, pharma-linked demand engine that the listed company never had.
-
Operating leverage after deleveraging: gross margin had already reached 40% in H1 2023, and with net debt near zero after equitisation the business no longer carries the EUR 132M bond burden that drove its losses.
-
Menu expansion into signatures and early detection (Mayo, MCW, City of Hope, Discovery Life Sciences) widens the addressable use of the 2,200-plus installed base.
Bear case
-
NGS displacement: single-gene and small-panel PCR keeps losing share to comprehensive genomic profiling, capping Idylla's long-run relevance in lung cancer.
-
Track record of missed targets: 2022 product revenue fell short of guidance by EUR 5–10M, and the end-2024 break-even target slipped.
-
Financial-sponsor ownership (KBC names Whitebox and Highbridge) may underinvest in R&D and seek an exit. That creates strategic uncertainty and possible relocation of value outside Belgium.
Catalysts and monitorables (next 12 months)
-
US commercial uptake of Idylla CDx MSI and any reimbursement coding decisions.
-
Progress on the ESR1 assay and AstraZeneca EGFR CDx toward FDA submission.
-
Any announcement of break-even, new financing or sale of Biocartis Holdings Inc.
-
Liquidator's progress and final closure of Biocartis Group NV, including any creditor distributions.
-
New IVDR certifications across the remaining CE-IVD menu.
-
Headcount and site decisions in Mechelen.
Analyst verdict
For holders of Biocartis Group NV, the investment case is closed. The October 2023 enforcement moved every share of the operating subsidiaries, and the group's cash, to the bondholders' vehicle. The December 2025 judicial dissolution confirmed negative net equity, and shareholders were told from September 2023 that they would receive nothing. The BCART line, ISIN BE0974281132, should be treated as a zero-value legal shell. Its only remaining relevance is to creditors following the liquidator's work and to tax-loss crystallisation for former holders.
The more interesting analytical question is why a technically elegant franchise failed as a listed equity. The data point to a capital structure mismatch, not a failed product:
-
Revenue compounded at about 15% a year from 2019 to 2022.
-
Oncology ASPs rose.
-
Product gross margins roughly doubled to the mid-30s, and reached 40% in H1 2023.
But R&D ran at about 100% of revenue for years, and a EUR 150M convertible issued in 2019 assumed a growth curve the market never delivered. When the 2022 guidance miss coincided with tighter capital markets, the equity was subordinated to debt it could not refinance.
The private successor is better positioned than its predecessor ever was:
-
It is effectively unlevered.
-
It holds the first FDA-approved fully automated cartridge CDx for colorectal cancer, plus IVDR CDx certifications.
-
It has a widening academic and biopharma partner network.
Its structural challenge remains intact, however. Idylla must defend a speed-and-simplicity niche as oncology testing standardises on NGS, under owners whose horizon is likely an exit rather than decades of platform building. Verdict: listed entity, no value (liquidation). Operating franchise, a credible niche survivor whose next 12–18 months of CDx uptake will decide whether it is sold as a growth asset or as a distressed technology tuck-in.
SOURCE LOG (primary first)
-
Biocartis Group NV: regulated release, judicial dissolution and liquidator appointment (17 December 2025), Euronext.
-
Biocartis Group NV: postponement of 2023 annual report and AGM (9 May 2024).
-
Biocartis Group NV: enforcement by secured creditors (31 October 2023), VFB (Dutch version).
-
Biocartis Group NV: recapitalisation agreement and H1 2023 results (26 September 2023), VFB; 360Dx summary.
-
Biocartis Group NV: FY2022 results and 2023 outlook (23 February 2023), Euronext/VFB.
-
Biocartis Group NV: 2022 key objectives (17 January 2023).
-
Biocartis Group NV: Q1 2023, Q3 2022, H1 2022 and Q1 2022 updates.
-
Biocartis Group NV: FY2021 results (24 February 2022) and FY2019 results (5 March 2020), GlobeNewswire.
-
Biocartis Group NV: CEO appointment, Roger Moody (11 April 2023).
-
Transparency notification, JJDC (3 October 2023); JPMorgan and Invesco (10 January 2024).
-
Euronext: Biocartis IPO release (2015).
-
FSMA: trading suspension notice (17 November 2016).
-
Biocartis.com newsroom (2025–2026 releases); Roger Moody biography page.
-
GenomeWeb / 360Dx: annual and half-year results coverage 2019–2023; CEO interview (September 2025).
-
BioWorld: FDA approval of Idylla CDx MSI; Apis agreement and CEO change; GeneFusion CE mark.
-
Made in (Mediahuis): KBC Securities commentary (28 August 2025); 2017 CEO appointment article.
-
Aggregators (lower confidence): Yahoo Finance (BIOGF profile), Parqet, Craft, roic.ai, financialfilings.com, CB Insights, sustainabilityreports.com.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Governance Detail
| Role | Name | Since | Notes |
|---|---|---|---|
Court-appointed liquidator | Kristiaan Caluwaerts (legaloffice.be) | 15 December 2025 | Replaces the board's management powers for liquidation purposes |
Board (pre-liquidation, last known) | — | 2023 | Composition at dissolution not publicly disclosed in sources reviewed |
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education |
|---|---|---|---|---|
Roger Moody | Chief Executive Officer | Since 24 April 2023 | CEO of GlySure Ltd (assets sold to Baxter); CFO of Nanosphere (now DiaSorin), Clinical Genomics and Talis Biomedical; early career at IBM Global Services | BS Finance, Syracuse University; MBA, University of Chicago Booth |
Michael Korn, M.D. | Chief Medical and Scientific Officer | In role by March 2025 | — | M.D. |
Ben Svarczkopf | SVP, Global Marketing | Since June 2025 | — | — |
Mike Kreitzinger | SVP, Global Business Development | Since August 2025 | — | — |
CFO | Vacant / not publicly disclosed | Prior CFO resigned 2023 | — | — |
“—” = not publicly disclosed.
Leadership History
| CEO | Period | Context |
|---|---|---|
Rudi Pauwels (founder) | 2010–2011 and later executive chairman roles | Founder; stepped back to a strategy-committee chair role |
Nayan Gregory Parekh | From November 2011 | Finance and corporate-development background (Novartis, New Rhein Healthcare) |
Rudi Pauwels (CEO at IPO) | Through 2016 | Led the 2015 IPO |
Hilde Windels (interim) | Around 2016–2017 | Former CFO and deputy CEO |
Herman Verrelst | August 2017 – April 2023 | Commercial expansion, US direct model, 2022 recapitalisation |
Roger Moody | April 2023 – present | Restructuring, creditor takeover, CDx pivot |
Major Shareholders
| Holder | Stake / position | Date | Source |
|---|---|---|---|
Johnson & Johnson Innovation – JJDC, Inc. | 3,843,804 shares (about 4.1% of about 93.9M) | 15 September 2023 | Transparency notification, 3 October 2023 |
JPMorgan Chase & Co. | — | January 2024 | Transparency notification, 10 January 2024 |
Invesco Ltd. | — | January 2024 | Transparency notification, 10 January 2024 |
Competitive Landscape
Key Competitors
| Competitor | Overlap with Idylla | Relative positioning |
|---|---|---|
Cepheid (Danaher) | GeneXpert cartridge PCR: the dominant rapid sample-to-answer platform; strong in infectious disease, with some oncology assays | Massive installed base; won the infectious-disease segment Biocartis exited |
Qiagen | therascreen PCR CDx kits (EGFR, KRAS, PIK3CA), QIAstat-Dx syndromic, NGS | Incumbent CDx partner of pharma; lab-based workflows |
Roche Diagnostics | cobas EGFR / KRAS / BRAF mutation tests; FoundationOne (Foundation Medicine) | Global scale; FDA CDx portfolio; channel power |
Thermo Fisher Scientific | Oncomine Dx Target Test, Genexus integrated NGS | NGS-based multi-gene CDx displacing single-gene PCR |
Illumina | TruSight Oncology NGS panels | Comprehensive genomic profiling trend |
Agilent (Dako) | IHC for MMR/MSI (Dako Omnis); also NGS | Competing modality for MSI (IHC versus PCR) |
Foundation Medicine (Roche) | Central-lab comprehensive genomic profiling, tissue and liquid | Send-out alternative to in-house testing |
Guardant Health | Liquid-biopsy CGP (Guardant360) | Competes in EGFR and other mutation detection |
bioMérieux (BioFire) | Syndromic infectious-disease PCR | Former infectious-disease competitor |
Seegene / Hologic / DiaSorin | Infectious-disease and molecular PCR | Former infectious-disease competitors |
Exact Sciences | Former partner (Genomic Health); OncoExTra CGP; colorectal screening | Named competitor by CB Insights |
Peer Comparison FY2021
| Company | Latest annual revenue | Growth | Profitability | R&D intensity |
|---|---|---|---|---|
Biocartis (FY2022, last full audited year) | EUR 57.5M | +19% | Net margin about -83%; product gross margin about 34% | R&D about 99% of revenue (FY2021) |
Recent Developments
Earlier restructuring events are therefore included at the end for context.



